ATCOR is the gold standard in non-invasive vascular biomarker technologies.
ATCOR improves the lives of patients through precision monitoring using digital vascular biomarkers.
For 30 years, ATCOR’s SphygmoCor® technology has been used by researchers and clinicians to collect and assess clinically relevant digital vascular biomarkers that help facilitate better routine patient monitoring. These biomarkers provide efficacy and safety insights that may optimize identification of the target population with the highest benefit-risk of a therapeutic intervention.
Digital vascular biomarkers also provide better prognostic and diagnostic information to target interventions—complementary and additive to—standard brachial blood pressure measurements. For over twenty years, major medical and research institutions have been using ATCOR’s SphygmoCor® systems to improve therapeutics and treatment strategies for the world’s most devastating chronic diseases. Leading pharmaceutical companies also utilize ATCOR biomarkers as primary, secondary, and safety clinical trial protocol endpoints.
Playing an integral role in over 4000+ studies to date, our technology has been referenced in over 7000 citations in leading medical journals.
ATCOR is a subsidiary of the Australian listed company CardieX Limited (ASX.CDX) www.cardiex.com